{"name":"Alector, Inc.","slug":"alector","ticker":"ALEC","exchange":"NASDAQ","domain":"alector.com","description":"Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevati","hq":"South San Francisco, CA","founded":0,"employees":"103","ceo":"Arnon Bhattacharyya","sector":"Biotech","stockPrice":2.31,"stockChange":0.16,"stockChangePercent":7.44,"marketCap":"$256M","metrics":{"revenue":21045000,"revenueGrowth":-71.5,"grossMargin":0,"rdSpend":123065000,"netIncome":-142929000,"cash":65802000,"dividendYield":0,"peRatio":-3.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"AL001 patent cliff ($0.00 at risk)","drug":"AL001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Alector Announces FDA Clearance of Investigational New Drug (IND) Application for AL002","summary":"Alector announced that the FDA has cleared the IND application for AL002, a tau-targeting antibody for the treatment of frontotemporal dementia.","drugName":"","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Alector Reports Third Quarter 2022 Financial Results","summary":"Alector reported its third-quarter 2022 financial results, with a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"Alector Enters into Collaboration and License Agreement with Biogen","summary":"Alector entered into a collaboration and license agreement with Biogen to develop and commercialize AL001 for the treatment of Alzheimer's disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdEc1aktTZjRfbWNCTy1WNFJpMmFHX3ZVNmxxZVhVYlV0VVRLQl9Gb29fdjh5Z2NVWWs3dzNlZ0xaeS1TOU1tLVpWMU9BYmxQWE44OHRLRi1DbjI4R04zaVNwM25kNy1IeUs5XzBGbFdYcnc5LXNZRF8xaXk2S1BHTGt3YVpYMEdJ?oc=5","date":"2026-03-04","type":"pipeline","source":"Yahoo Finance","summary":"How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve - Yahoo Finance","headline":"How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"earnings","source":"simplywall.st","summary":"There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st","headline":"There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOaTY4WlFnR3lCcnJhcUVRdHI4MHV6XzM1cVd1WW12dVE4eDFVQW40d3ZuVTIxeTlyQUhxdGdZRy0yZEhGUmYwbmFnU0UwRkEyZUlEeG5JbEVBbEM0eWNyZGxQTTgzQkZQa1lrMjk5Vy1laHhNM3gtZ1YxWEJUVF9Tbmo2b1JodFpFS0dnZmdndXlOcnVQdjIwVUs0aw?oc=5","date":"2025-11-18","type":"pipeline","source":"Finviz","summary":"Alector Stock Plummets 63% in a Month: Here's What You Need to Know - Finviz","headline":"Alector Stock Plummets 63% in a Month: Here's What You Need to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1kNktCYkFRMDgxUUR6MV9iVFNaVGRVQ29fNWJqR0tHQWY4bm5WTzQ1QzhVNWlsV3U5SkZubUVkdjBQcVR3bDFjeUNLajRKRFBpTWQzeEpXQ2xtTmlGUExaMVBNZlY0YXFzb0VlSmNGRVhfdw?oc=5","date":"2025-10-22","type":"pipeline","source":"StocksToTrade","summary":"Alector’s Turbulent Ride: Is Recovery Possible? - StocksToTrade","headline":"Alector’s Turbulent Ride: Is Recovery Possible?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdVUxRHFCSHVqZUlwWS1FRGgydmc2dHNTdk5BNG5DNUNFR1ptQjAwS2h1YzhDWWFhXzRJajBDUFE2NFdtVkdoVjNtVW1qZ0JmMjdxVmx1U0o0RExiZjZJZldzLU1JN2ZrbVhvSDhMMUxRQTh5ZndmdjUtcGN1Y2tNODlZQ29XVU9jVXpiLUNJbzA0VGNPSWJIcmZTMTczWUFtWk9jZU1nZw?oc=5","date":"2025-10-22","type":"trial","source":"BioPharma Dive","summary":"Alector dementia drug, partnered with GSK, fails in key study - BioPharma Dive","headline":"Alector dementia drug, partnered with GSK, fails in key study","sentiment":"negative"},{"url":"https://news.google.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?oc=5","date":"2025-07-11","type":"pipeline","source":"simplywall.st","summary":"3 Penny Stocks With Market Caps Over $80M To Watch Closely - simplywall.st","headline":"3 Penny Stocks With Market Caps Over $80M To Watch Closely","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNSzVCeHFhbXBGcGF4NTkzMW5TNFU5MnM5azZJb0UxbXBaOUpaV2Jab0dvZ3FaUTN4UW52d2Z1b1BSUmlIRHVhVjU2WUpvZ3lfMzZKUXYyT2tHZHRjVkdXMUluTkkzYl9uMTQ3cXVsRUxHUWhMcEI0a1AyUzlsZ3M1aXpQODNTbDM3Vk50OXNkOUs4dlVOcnpSZ2o5YTFwb3NCUmI1a0FsSU5KOWNjN1cyY0Jn?oc=5","date":"2025-03-13","type":"trial","source":"Seeking Alpha","summary":"Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point (NASDAQ:ALEC) - Seeking Alpha","headline":"Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point (NASDAQ:ALEC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9WOUlLdUdpTnc2YVlYdUw5cTQ4MlRQUGhMUlh6aEN4ejY3a2hLR1lReGRSQ00yWURYQXhjNlhiWHhkZUJ5M0dLSkQ5QWVOYm5z?oc=5","date":"2024-02-14","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQNFE4Z0NtMWdFZFVKODBiWU9RVXVMdkt2YVhEYnlrZTVNaWpiY2dOMklWQmhZc0s4b2w3dElWVjlzSDZyamVlOUx2eFhBN2FUWm4yWFFpa3VuQzNRWWpSeXJrVXdFTXpSOTVqRklHZHNPQngycGpZTlZ6aHNiTDRQSGZNbzhHbS1HbFNnN09wdk5mdGhHNENlWng3OUQ5Z0hyejlzY2lOZE1hWEUzeUVmazYtbmhaMjJyWDV1TDBRV19Qd1Q3MTlka2M1Yw?oc=5","date":"2021-07-02","type":"deal","source":"reuters.com","summary":"GSK, Alector to develop Parkinson's, Alzheimer's drugs in $2.2 bln deal - reuters.com","headline":"GSK, Alector to develop Parkinson's, Alzheimer's drugs in $2.2 bln deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOci1RVUJlRmhqdUR3VXZKb3EyOEFfQWl4b0FIMnpjaDUzRU54bkZMQ2ZON1RtZHpvZzBlZUF3WFRVX1c5TlFDa3NiRG1ZUGlIUE5YRnluZnNzM1JHUjBvckd6Z1c2OGdFendzbHdCXzdSWmhPalgyNUl5dnFTYWwwdWY4RGpMb0VTNzRkTDBxclJwdTR0c1FjUnlzUEtUX2U3b2RaR0JlRjcwbjY3VnM5UUg2Ry1RX19XNUxUSg?oc=5","date":"2021-07-02","type":"deal","source":"Fierce Biotech","summary":"GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's - Fierce Biotech","headline":"GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOZkZjamJoOEZEMHplQm5PVjR1ejFoQUhEWHlaUXdJcVhVT0dSX3BQb3VGaWd6aGh2UVZ4TlhPNmRfeENGRnY1SVF0a1ZVUUF1YUlNVTJYWXowYzdQQzYzeWpSV0k4a19kdzEtWTlTOVprclhfRUVIc21LRHNLWUpyTTZqemZMbkE0c3Fsek1VV01CeFhfXzdDdDJrTkh1THBRb0RNTWhnaFJENGdabE1fZGNB?oc=5","date":"2021-07-02","type":"deal","source":"The Business Journals","summary":"Peninsula biotech, Big Pharma ink $700M upfront deal around neurodegenerative diseases - The Business Journals","headline":"Peninsula biotech, Big Pharma ink $700M upfront deal around neurodegenerative diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNS3NOd1NaaTdpdzFCWUdsaHh2ZUFObk1mU1FqckhteVNxTUxMNy1kY0dDMFZodmFxRXVaN0NtZ3Nkdnp2dW1iMFg0SWI4amZSOEpZenRaSTA2U0Q3dnpwNVVFWGVoZEVWdURfUFFUbzFHWUdqUGFIamVnVEZxZ0F3SQ?oc=5","date":"2020-04-28","type":"pipeline","source":"MarketBeat","summary":"Top Alector (ALEC) Competitors 2026 - MarketBeat","headline":"Top Alector (ALEC) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"AL001","drugSlug":"tau-targeting-antibody","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Eli Lilly and Company","Roche Holding AG"],"therapeuticFocus":["Tauopathies","Neurodegenerative diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":21045000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":21045000,"period":"2025-12-31"},{"value":100600000,"period":"2024-12-31"},{"value":97100000,"period":"2023-12-31"},{"value":133600000,"period":"2022-12-31"},{"value":21098000,"period":"2020-12-31"},{"value":21219000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":123065000,"rdSpendHistory":[{"period":"2025-12-31","value":123065000},{"period":"2024-12-31","value":185940000},{"period":"2023-12-31","value":192115000},{"period":"2022-12-31","value":210418000}],"sgaSpend":53987000,"operatingIncome":-156007000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-156007000},{"period":"2024-12-31","value":-144997000},{"period":"2023-12-31","value":-151740000},{"period":"2022-12-31","value":-137834000}],"netIncome":-142929000,"netIncomeHistory":[{"period":"2025-12-31","value":-142929000},{"period":"2024-12-31","value":-119049000},{"period":"2023-12-31","value":-130391000},{"period":"2022-12-31","value":-133310000}],"eps":-1.39,"epsHistory":[{"period":"2025-12-31","value":-1.39},{"period":"2024-12-31","value":-1.23},{"period":"2023-12-31","value":-1.56},{"period":"2022-12-31","value":-1.62}],"cash":65802000,"cashHistory":[{"period":"2025-12-31","value":65802000},{"period":"2024-12-31","value":33021000},{"period":"2023-12-31","value":74555000},{"period":"2022-12-31","value":154323000}],"totalAssets":293237000,"totalLiabilities":262588000,"totalDebt":36233000,"equity":30649000,"operatingCashflow":-184031000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-184031000},{"period":"2024-12-31","value":-229905000},{"period":"2023-12-31","value":-184162000},{"period":"2022-12-31","value":-20329000}],"capex":-41000,"capexHistory":[{"period":"2025-12-31","value":-41000},{"period":"2024-12-31","value":-1255000},{"period":"2023-12-31","value":-2381000},{"period":"2022-12-31","value":-4117000}],"freeCashflow":-184072000,"dividendsPaid":null,"buybacks":null,"employees":103,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":13340000,"ebit":-39566000,"ebitda":-37307000,"period":"2025-12-31","revenue":6237000,"epsBasic":-0.34,"netIncome":-37267000,"rdExpense":32463000,"epsDiluted":-0.34,"grossProfit":null,"operatingIncome":-39566000},{"sga":11518000,"ebit":-37608000,"ebitda":-35276000,"period":"2025-09-30","revenue":3260000,"epsBasic":-0.34,"netIncome":-34667000,"rdExpense":29350000,"epsDiluted":-0.34,"grossProfit":null,"operatingIncome":-37608000},{"sga":14401000,"ebit":-34138000,"ebitda":-30916000,"period":"2025-06-30","revenue":7874000,"epsBasic":-0.3,"netIncome":-30524000,"rdExpense":27611000,"epsDiluted":-0.3,"grossProfit":null,"operatingIncome":-34138000},{"sga":14728000,"ebit":-44695000,"ebitda":-42847000,"period":"2025-03-31","revenue":3674000,"epsBasic":-0.41,"netIncome":-40471000,"rdExpense":33641000,"epsDiluted":-0.41,"grossProfit":null,"operatingIncome":-44695000},{"sga":15028000,"ebit":-7249000,"ebitda":-5171000,"period":"2024-12-31","revenue":54240000,"epsBasic":-0.02,"netIncome":-2074000,"rdExpense":46461000,"epsDiluted":-0.02,"grossProfit":null,"operatingIncome":-7249000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.31,"previousClose":2.15,"fiftyTwoWeekHigh":3.4,"fiftyTwoWeekLow":1.01,"fiftyTwoWeekRange":"1.01 - 3.4","fiftyDayAverage":2.3,"twoHundredDayAverage":2.09,"beta":0.65,"enterpriseValue":66737152,"forwardPE":-3.3,"priceToBook":24.52,"priceToSales":13.9,"enterpriseToRevenue":3.62,"enterpriseToEbitda":-0.52,"pegRatio":0,"ebitda":-127494000,"ebitdaMargin":0,"freeCashflow":-119106128,"operatingCashflow":-173060992,"totalDebt":34548000,"debtToEquity":332.8,"currentRatio":5.25,"returnOnAssets":-25.7,"returnOnEquity":-238.9,"analystRating":"2.6 - Hold","recommendationKey":"hold","numberOfAnalysts":5,"targetMeanPrice":3.1,"targetHighPrice":6,"targetLowPrice":1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":9.6,"institutionHeldPercent":81,"sharesOutstanding":111025187,"floatShares":87233600,"sharesShort":4999721,"shortRatio":7.92,"shortPercentOfFloat":4.5,"epsTrailing":-1.19,"epsForward":-0.7,"revenuePerShare":0.17,"bookValue":0.09,"officers":[{"age":69,"name":"Dr. Arnon  Rosenthal Ph.D.","title":"Co-Founder, CEO & Director"},{"age":51,"name":"Mr. Neil  Berkley M.B.A., M.S.","title":"CFO & Chief Business Officer"},{"age":null,"name":"Ms. Katie  Hogan","title":"Senior Director of Corporate Communication & Investor Relations"},{"age":null,"name":"Ms. Danielle  Pasqualone J.D., Ph.D.","title":"General Counsel"},{"age":null,"name":"Ms. Clare  Hunt M.B.A.","title":"Chief People & Places Officer"},{"age":null,"name":"Ms. Kristina  Cutter M.P.H.","title":"Chief Development Officer"},{"age":null,"name":"Mr. Giacomo  Salvadore M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Hua  Long DABT, Ph.D.","title":"Senior VP & Head of Research"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.alector.com","phone":"415 231 5660"}}